Sale!

Immunohistochemistry Prostate Benign vs Malignant Panel Test

Original price was: $212.Current price is: $126.

-41%

The Immunohistochemistry Prostate Benign vs Malignant Panel Test is a specialized diagnostic tool that helps pathologists distinguish between benign prostate conditions and malignant prostate cancer. This test utilizes three key biomarkers – AMACR, CK5/6, and p63 – to provide definitive diagnosis when standard histopathology results are inconclusive. By analyzing tissue samples through advanced immunohistochemistry techniques, this panel offers critical information for treatment planning and prognosis assessment. The test is particularly valuable for patients with ambiguous biopsy results or those requiring confirmation of prostate cancer diagnosis. Available for only $126 USD, this comprehensive panel delivers reliable results within 5-7 days, helping healthcare providers make informed decisions about patient care and treatment strategies.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

Immunohistochemistry Prostate Benign vs Malignant Panel Test

Comprehensive Prostate Cancer Diagnostic Testing

The Immunohistochemistry Prostate Benign vs Malignant Panel Test represents a significant advancement in prostate cancer diagnostics, providing pathologists and oncologists with definitive tools to distinguish between benign prostate conditions and malignant prostate cancer. This specialized panel employs cutting-edge immunohistochemistry techniques to analyze tissue samples with unprecedented accuracy, ensuring patients receive the correct diagnosis and appropriate treatment recommendations.

What This Test Measures and Detects

This comprehensive panel evaluates three critical biomarkers that play essential roles in prostate tissue differentiation:

  • AMACR (Alpha-Methylacyl-CoA Racemase): This biomarker is typically overexpressed in prostate cancer cells but shows minimal expression in benign prostate tissue, serving as a reliable indicator of malignancy.
  • CK5/6 (Cytokeratin 5/6): These cytokeratins are expressed in basal cells of benign prostate glands but are typically lost in prostate adenocarcinoma, helping confirm malignant transformation.
  • p63: This nuclear protein is expressed in basal cells of benign prostate tissue and serves as an additional marker to confirm the absence of basal cells in prostate cancer.

Who Should Consider This Test

This specialized diagnostic panel is recommended for patients experiencing:

  • Elevated PSA levels with ambiguous biopsy results
  • Suspicious prostate lesions identified during imaging studies
  • Atypical small acinar proliferation (ASAP) on initial biopsy
  • High-grade prostatic intraepithelial neoplasia (HGPIN)
  • Previous inconclusive prostate biopsy results
  • Monitoring of prostate cancer recurrence
  • Evaluation of treatment response in diagnosed prostate cancer cases

Key Benefits of the Prostate Benign vs Malignant Panel

  • Enhanced Diagnostic Accuracy: Provides definitive differentiation between benign and malignant prostate tissue
  • Precision Treatment Planning: Enables oncologists to develop targeted treatment strategies based on accurate diagnosis
  • Reduced Diagnostic Uncertainty: Minimizes the risk of misdiagnosis and unnecessary treatments
  • Comprehensive Biomarker Analysis: Evaluates multiple markers simultaneously for comprehensive assessment
  • Improved Patient Outcomes: Facilitates early and accurate diagnosis leading to better treatment outcomes

Understanding Your Test Results

Your test results will provide detailed information about the expression patterns of AMACR, CK5/6, and p63 in your prostate tissue sample:

  • Benign Pattern: Typically shows positive staining for CK5/6 and p63 in basal cells, with negative or weak AMACR staining
  • Malignant Pattern: Usually demonstrates positive AMACR staining with loss of CK5/6 and p63 expression in basal cells
  • Intermediate Patterns: Some cases may show mixed patterns requiring correlation with clinical findings and additional testing

Your healthcare provider will interpret these results in the context of your clinical history, physical examination findings, and other diagnostic tests to provide comprehensive care recommendations.

Test Pricing Information

Test Name Discount Price Regular Price
Immunohistochemistry Prostate Benign vs Malignant Panel Test $126 USD $212 USD

Nationwide Testing Availability

We have diagnostic centers conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our nationwide network ensures that patients can access this advanced diagnostic testing regardless of their location.

Schedule Your Test Today

Take the first step toward accurate prostate cancer diagnosis and appropriate treatment planning. Our experienced team is ready to assist you with scheduling your Immunohistochemistry Prostate Benign vs Malignant Panel Test. Contact us today to book your appointment and receive the comprehensive diagnostic information you need for informed healthcare decisions.

Call or WhatsApp us at +1(267) 388-9828 to schedule your test or for any questions about the Immunohistochemistry Prostate Benign vs Malignant Panel.